# Vesalio

> Vesalio is a Plano-based medical device company making mechanical thrombectomy tools for stroke, coronary and peripheral vascular care. Its Drop Zone design aims to capture difficult clots and retain fragments during retrieval; its portfolio includes NeVa, enVast and pVasc.

- **Founded:** 2017
- **Headquarters:** Plano, United States
- **Founders:** Arthur J. Ulm (Founder and CTO)
- **Products:** NeVa, NeVa NET, NeVa VS, pVasc, enVast
- **Notable:** FDA humanitarian device exemption for NeVa VS in September 2022., CE mark for NeVa NET in 2022., NeVa CLEAR study reported first-pass eTICI 2b-3 reperfusion in 73.8% of its 107-patient primary analysis group.

## Products & services

- **NeVa** — CE-marked stent retriever for acute ischemic stroke, with open Drop Zone pockets for clot capture; not FDA cleared in the United States.
- **NeVa NET** — CE-marked NeVa variant with an integrated distal microfilter designed to retain clot fragments; not FDA cleared in the United States.
- **NeVa VS** — Retrievable device for adjunct treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage under an FDA humanitarian device exemption; CE marked in 2026.
- **pVasc** — Mechanical thrombectomy device for peripheral arterial thrombi and emboli, launched in the United States.
- **enVast** — Stent-based coronary clot retriever, CE marked and FDA 510(k) cleared.
- **pVasc NET** — Peripheral clot retriever with integrated distal filter, FDA 510(k) cleared.
- **NeVasc** — Aspiration catheter platform for vascular intervention.

## Achievements

- FDA humanitarian device exemption for NeVa VS in September 2022.
- CE mark for NeVa NET in 2022.
- NeVa CLEAR study reported first-pass eTICI 2b-3 reperfusion in 73.8% of its 107-patient primary analysis group.
- pVasc launched in the United States in 2024.
- FDA 510(k) clearance for enVast in December 2025.
- FDA 510(k) clearance for pVasc NET in August 2026.
- NATURE randomized 154 patients at 11 centers and reported a nearly 26% reduction in its CK-MB-based infarct-size endpoint in August 2026.
- Company reported use in more than 20,000 patients across more than 60 countries in August 2026.

## Latest updates

- **2026-08** — NATURE randomized trial met its CK-MB-based primary endpoint for enVast-assisted thrombectomy in large-thrombus STEMI.
- **2026-08** — FDA granted 510(k) clearance to pVasc NET with an integrated distal filter.
- **2026-07** — Greg Cook joined as chief commercial officer.
- **2026-02** — NeVa VS and NeVa 3.0 mm received CE marks; aspiration catheter indications expanded in the United States.
- **2025-12** — FDA granted enVast 510(k) clearance for coronary thrombectomy.

## Links

- Website: https://www.vesalio.com/
- LinkedIn: https://www.linkedin.com/company/vesalio
- Twitter/X: https://twitter.com/vesalio_neva
- Facebook: https://www.facebook.com/Vesalio-1878291765747392/

---

Profile page: https://yespress.io/vesalio
Published by YesPress — https://yespress.io
Last updated: 2026-09-29